Oculis (OCS) BofA Securities 2025 Healthcare Conference summary

Portfolio overview and financial position

• Focus on ophthalmology and neuro-ophthalmology with three core assets, each targeting multiple indications.

• Strong balance sheet with $206 million in cash and no debt, providing runway into early 2028.

• All assets are first-in-class, addressing significant unmet medical needs.

• Supported by experienced management and leading healthcare investors.

OCS-01 for diabetic macular edema (DME)

• OCS-01 is a high-concentration dexamethasone eye drop, first to reach the back of the eye, targeting DME.

• Addresses a large, underserved market where current treatments are invasive and compliance is low.

• Phase III stage one showed 7.6 letter gain in visual acuity at 12 weeks and strong retinal thickness improvement.

• Well tolerated with no unexpected adverse events; rapid phase III stage two enrollment completed with over 800 patients.

• Phase III results expected Q2 2025, with NDA filing planned for H2 2025.

Privosegtor (OCS-05) for neuroprotection

• Privosegtor is a neuroprotective peptide targeting acute optic neuritis, with orphan drug designation.

• Phase II showed 43% improvement in ganglion cell layer thickness and 18-letter visual acuity gain at six months.

• Consistent benefits across patient subgroups and endpoints, including neurofilament reduction.

• Plans to expand into multiple sclerosis relapses and NAION, with FDA meetings and IND readiness in 2025-2026.